Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Mallinckrodt
Harvard Business School
Baxter
Moodys
Dow

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

Details for Biologics License Application: 103234

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for BLA: 103234
Tradename:EPOGEN/PROCRIT
Applicant:Amgen
Ingredient:epoetin alfa
Patents:85
Approval Date:Jun 01, 1989
Suppliers: see list2
Pharmacology for BLA: 103234

US Patents for BLA: 103234

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen EPOGEN/PROCRIT epoetin alfa VIAL; SINGLE-USE 103234 001 1989-06-01   Start Trial SIO2 MEDICAL PRODUCTS, INC. (Auburn, AL) 2033-03-11 RX search
Amgen EPOGEN/PROCRIT epoetin alfa VIAL; SINGLE-USE 103234 001 1989-06-01   Start Trial AMGEN INC. (Thousand Oaks, CA) 2039-02-26 RX search
Amgen EPOGEN/PROCRIT epoetin alfa VIAL; SINGLE-USE 103234 001 1989-06-01   Start Trial 2036-04-01 RX search
Amgen EPOGEN/PROCRIT epoetin alfa VIAL; SINGLE-USE 103234 001 1989-06-01   Start Trial MIDWESTERN UNIVERSITY (Downers Grove, IL) 2027-08-21 RX search
Amgen EPOGEN/PROCRIT epoetin alfa VIAL; SINGLE-USE 103234 001 1989-06-01   Start Trial YALE UNIVERSITY (New Haven, CT) 2039-02-26 RX search
Amgen EPOGEN/PROCRIT epoetin alfa VIAL; SINGLE-USE 103234 001 1989-06-01   Start Trial GENOSCIENCE PHARMA (Marseilles, FR) 2039-02-26 RX search
Amgen EPOGEN/PROCRIT epoetin alfa VIAL; SINGLE-USE 103234 001 1989-06-01   Start Trial ChemoCentryx, Inc. (Mountain View, CA) 2036-06-13 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Harvard Business School
Merck
Medtronic
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.